Trevor Allred
Stock Analyst at Oppenheimer
(4.68)
# 170
Out of 5,115 analysts
15
Total ratings
86.67%
Success rate
39.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Initiates: Outperform | $75 | $17.50 | +328.57% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $10.21 | +76.30% | 1 | Jan 7, 2026 | |
| TBPH Theravance Biopharma | Initiates: Outperform | $27 | $18.94 | +42.56% | 1 | Dec 3, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $250 → $275 | $192.10 | +43.15% | 8 | Nov 7, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $36.85 | +117.10% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $76.80 | +10.68% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $20.00 | +75.00% | 1 | Aug 11, 2025 |
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $17.50
Upside: +328.57%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $10.21
Upside: +76.30%
Theravance Biopharma
Dec 3, 2025
Initiates: Outperform
Price Target: $27
Current: $18.94
Upside: +42.56%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Outperform
Price Target: $250 → $275
Current: $192.10
Upside: +43.15%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $36.85
Upside: +117.10%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $76.80
Upside: +10.68%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $20.00
Upside: +75.00%